Clene Inc. CLNN Archives - Page 6 of 10

WednesdayMay 22, 2024 3:45 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Looking to Transform Healthcare for Individuals with Neurodegenerative Diseases

Clene (NASDAQ: CLNN) has innovated CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, which is a significant advancement for the treatment of neurodegenerative disease. “The inspiration for CNM-Au8 comes from the therapeutic potential of elemental metals, a concept understood in both Western and Eastern medicine traditions. Clene’s approach, which leverages nanotechnology, focuses on improving mitochondrial function to support the complex electrical activity necessary for movement, cognitive function and more. Clene’s CEO, Rob Etherington, highlighted that CNM-Au8 is tailored to address the central nervous system needs, targeting diseases like ALS and MS… Clinical trials of CNM-Au8 have shown…

TuesdayMay 21, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Key Operational Highlights as part of First Quarter 2024 Financial Results

Clene presented clinical data at the 2024 American Academy of Neurology (“AAN”) Annual Meeting, demonstrating that long-term CNM-Au8® treatment resulted in significant evidence of repair and remyelination across multiple paraclinical endpoints Clene entered into a sub-award grant agreement with Columbia University under the previously announced National Institute of Health (“NIH”) Grant Clene announced the publication of "Protein Corona Composition of Gold Nanocatalysts" in the ACS Pharmacology & Translational Science journal Clene (NASDAQ: CLNN), a late-stage clinical biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), along with its wholly-owned subsidiary…

WednesdayMay 01, 2024 2:26 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Spotlighted in a Recent ‘From Lab to Launch’ Podcast Release

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. Rob Etherington, President, Director and CEO of Clene, was featured in a recent release of From Lab to Launch, a podcast sharing the inspiring stories of founders, investors, scientists, engineers and pioneers in the life sciences sector. The podcast, hosted by Meg Sinclair, is available for on-demand listening on From Lab to Launch. During the interview, Etherington discussed Clene’s work to address the critical unmet medical…

WednesdayMay 01, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting

Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05) Significantly enhanced clinical outcomes were associated with long-term daily oral CNM-Au8(R) 30 mg treatment (change from original baseline; p < 0.05) Long-term administration of CNM-Au8, spanning up to three years, was well-tolerated, with no significant safety concerns identified This marks the first Phase 2 clinical trial in MS utilizing a non-immunomodulatory drug to achieve a clinical outcome demonstrating improved function supporting remyelination and reparative effects Clene (NASDAQ: CLNN), along with its…

MondayApr 22, 2024 10:30 am

Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease

CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization Treatment with CNM-Au8 investigated in clinical trials adjunctive to standard-of-care exhibits no known drug interactions, and aims to enhance function and survival Nearly 90,000 people are diagnosed with Parkinson's disease every year with no approved drug to slow or halt disease progression currently available The Parkinson's disease treatment market was valued at $4.61 billion in 2022 and is expected to reach $11.98 billion by 2030 In recognition of April as Parkinson’s Disease Awareness Month, IBN is highlighting Clene (NASDAQ: CLNN),…

ThursdayApr 11, 2024 3:51 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R) in 2024

Clene (NASDAQ: CLNN), alongside its wholly owned subsidiary Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. These include amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead candidate, CNM-Au8(R), is a gold nanocrystal suspension that has emerged as a promising candidate for the treatment of both ALS and MS… Despite the FDA’s decision in late 2023 against allowing Clene to move forward with an accelerated approval pathway based on initial biomarker data, Clene is diligently preparing supplemental data to provide additional supportive biomarker, survival and mechanistic…

TuesdayApr 09, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug

Clinical trials of Clene’s lead candidate CNM-Au8(R) have shown notable success in crossing the blood-brain barrier and enhancing the brain's bioenergetic metabolites, essentially "reversing the clock" on what would be considered healthy aging CNM-Au8 has shown promise in clinical trials for both ALS and MS, including improvements in survival rates and clinical function Clene was recently featured in an interview of CEO Rob Etherington on ‘First in Human’ podcast In a significant advancement for the treatment of neurodegenerative diseases, Clene (NASDAQ: CLNN) has innovated CNM-Au8, an oral nanotherapeutic designed to revitalize the brain's mitochondrial function. The potential of this drug…

TuesdayApr 02, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science

The publication provides a comprehensive analysis of proteins from human blood plasma that interact with CNM-Au8(R) CNM-Au8 nanocrystals coated with a protein corona are less prone to clumping compared to those without any coating Certain apolipoproteins found on the nanocrystals' surface, which aid in crossing the blood-brain barrier (“BBB”), were identified, suggesting an enhanced delivery mechanism into the brain The findings enrich the understanding of CNM-Au8's mechanism as preparations for a Phase 3 trial for ALS are underway, scheduled for the second half of 2024 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company…

TuesdayMar 26, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS

Clene’s recently released 2023 financial and operational updates highlight the company’s developments for the treatment of amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis CNM-Au8(R) functions as a neuroprotective and remyelinating therapy in neurodegenerative diseases Recent data from the randomized, double-blind, placebo-controlled HEALEY-ALS Platform Trial and its open-label extension, reported by Clene in December 2023, revealed encouraging outcomes on survival and delayed clinical worsening Clene recently provided perspectives on its achievements and the development path for CNM-Au8(R) during its participation in the 36th Annual ROTH Conference, which was held March 18-19, 2024 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene…

TuesdayMar 19, 2024 12:06 pm

QualityStocksNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, was featured in a recent episode of First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials. Hosted by Vial EVP Rich McCormick, the podcast is available for on-demand listening on First in Human by Vial. Rob Etherington, president, director and CEO of Clene joined the program to highlight information about the company’s work in the field of nanotechnology. “For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the…

Site Search

Company Search

Tag: Clene Inc. CLNN